CME; cisplatin-ineligible mUC; pembrolizumab; FGFR biomarkers; PD-L1 bladder cancer; FGFR-TKI

Advances in the Management of mUC: The State of the Union 

Advances in the Management of mUC: The State of the Union
RestartResume

What’s new in mUC? Explore case-based discussions and the latest clinical safety and efficacy data to discover evolving treatments and targets.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, most of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options. 

    This ECHO Certified activity is designed for clinicians who treat locally advanced or metastatic urothelial cancer. The content reinforces the information presented by Drs. Arjun Balar and Daniel Petrylak during their chapterized activity on new clinical trials and guidelines that align with the identified unmet need of subsequent treatment options for this patient population. The goal of that program, which is reiterated in this ECHO, is to enhance the knowledge and skills of clinicians through case-based content. The selected cases demonstrate individualized patient treatment plans to enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Arjun V. Balar, MD
    Associate Professor of Medicine
    NYU Langone Health
    New York, NY

    Contracted Research: AstraZeneca/MedImmune, Immunomedics/Gilead, Genentech, Merck, Nektar, Seagen
    Consulting Fees/Advisory Board: AstraZeneca/MedImmune, Bristol Myers Squibb, EpiVax Oncology, Genentech, Immunomedics/Gilead, Incyte, Istari Oncology, Janssen, Merck, Nektar, Pfizer, Seagen
    Speaker Engagement: AstraZeneca/Medimmune, Genentech, Merck
    Steering/ Scientific Advisory Committee: Merck, Nektar
    Ownership Interest: EpiVax Oncology

    Daniel P. Petrylak, MD
    Professor of Medicine
    Director, Genitourinary Oncology
    Co-Director, Signal Transduction Program, Yale University
    New Haven, CT

    Contracted Research: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics
    Consulting Fees: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, UroGen

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Devise first- and second-line treatment plans for patients with metastatic urothelial cancer 
    • Identify appropriate treatment options for patients with metastatic urothelial cancer previously treated with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor
    • Manage patients with metastatic urothelial carcinoma according to best practices for multidisciplinary care
  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from Astellas and SeaGen, and Gilead Sciences. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free